What is myopia, and why are myopia rates increasing in children around the world?
In this episode of Mission:Optician, host Gwen Cooper, executive director of United Opticians Association (UOA), sits down with Dr. Monica Jong, head of Medical Affairs, North America at EssilorLuxottica and a global leader in myopia management. Together, they break down the science, urgency, and real-world impact of myopia — especially in children.
Dr. Jong defines myopia in simple terms and explores why myopia rates are rising, including the role of environmental factors like increased screen time and reduced time outdoors. She reflects on new treatment innovations like the Essilor® Stellest® lens and what this lens means for the future of patient care.
They discuss the role of opticians in myopia management, how to communicate with parents, and why early intervention is key for children.
In this episode, you will learn:
What myopia is and how it affects long-term eye healthWhy myopia rates are rising globally and what’s driving this trendThe optician’s role in educating patients and improving myopia outcomesWhy comprehensive eye exams for children are more important than everThis episode is brought to you by EssilorLuxottica.
Join us at UOA’s One Vision | One Voice | One UOA Leadership Conference taking place June 25-27 in Chicago, where opticians, educators, and industry partners will gather to explore innovation, advocacy, and the future of the profession, including a special session with the Essilor® Stellest® Lens. Secure your spot: https://www.uoaleadership.org/
Learn more about UOA and join our growing community at https://opticians.org
Shape the conversation on Mission:Optician! Tell us what topics and guests you want us to feature next at https://opticians.org/podcast
The intent of this podcast is to educate eye care professionals (ECPs). Any advice provided is general in nature and ECPs should practice within their professional scope and in accordance with local regulations.
The Essilor® Stellest® spectacle lens is indicated for the correction of myopia with and without astigmatism and for slowing the progression of myopia in children with non-diseased eyes, who, at the initiation of treatment, are aged 6-12 years and have spherical equivalent refraction of -0.75 D to - 4.50 D with astigmatism up to 1.50 D.